	US 12,329,770 B2
	N4-hydroxycytidine and derivatives and anti-viral uses related thereto
George R. Painter, Atlanta, GA (US); Gregory R. Bluemling, Decatur, GA (US); Michael G. Natchus, Alpharetta, GA (US); and David Guthrie, Avondale Estates, GA (US)
Assigned to Emory University, Atlanta, GA (US)
Filed by EMORY UNIVERSITY, Atlanta, GA (US)
Filed on Dec. 20, 2023, as Appl. No. 18/390,347.
Application 18/390,347 is a continuation of application No. 17/465,344, filed on Sep. 2, 2021, granted, now 11,903,959.
Application 17/465,344 is a continuation of application No. 16/755,779, granted, now 11,331,331, issued on May 17, 2022, previously published as PCT/US2018/064503, filed on Dec. 7, 2018.
Claims priority of provisional application 62/760,434, filed on Nov. 13, 2018.
Claims priority of provisional application 62/626,998, filed on Feb. 6, 2018.
Claims priority of provisional application 62/595,907, filed on Dec. 7, 2017.
Prior Publication US 2024/0189335 A1, Jun. 13, 2024
Int. Cl. C07H 19/067 (2006.01); A61K 31/7068 (2006.01); A61P 31/12 (2006.01)

CPC A61K 31/7068 (2013.01) [A61P 31/12 (2018.01); C07H 19/067 (2013.01)]

11 Claims

1. A compound of Formula VI,

or a pharmaceutical or physiological salt thereof, wherein

R¹, R², and R³are each independently selected from the following:

optionally substituted carbonates, optionally substituted acetal, and optionally substituted hemiacetal,

wherein R¹, R², and R³are optionally substituted with one or more, the same or different, R¹⁰;

R⁶is alkyl, carbocyclyl, heterocarbocyclyl, alkoxy, carbocycloxy, heterocarbocycloxy, or cycloalkoxy, wherein R⁶is optionally substituted with one or more, the same or different, R¹⁰;

R¹⁰is alkyl, amino, carbocyclyl, heterocarbocyclyl, alkoxy, carbocycloxy, heterocarbocycloxy, cycloalkoxy, or carbonyl, wherein R¹⁰is optionally substituted with one or more, the same or different, R¹¹; and

R¹¹is hydroxy, alkyl, carbocyclyl, heterocarbocyclyl, alkoxy, carbocycloxy, heterocarbocycloxy, cycloalkoxy, or carbonyl.